FDA Accepts Supplemental Application for Biogen's SKYCLARYS
The FDA has accepted a supplemental application (NDA216718) for Biogen's SKYCLARYS, containing omaveloxolone.
Indication
Clinical and regulatory intelligence for Rare Disease with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.